A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Rachel J. Cook,Eytan M. Stein,David P. Steensma,Mikkael A. Sekeres,Dale Bixby,David A. Rizzieri,Joseph G. Jurcic,Carlos Enrique Vigil,Robert L. Redner,Gail J. Roboz,Michael R. Savona,Michael R. McKeown,Kristin Stephens,David A. Roth,Jorge E. Cortes

A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

2017

Rachel J. Cook
Eytan M. Stein
David P. Steensma
Mikkael A. Sekeres
Dale Bixby
David A. Rizzieri
Joseph G. Jurcic
Carlos Enrique Vigil
Robert L. Redner
Gail J. Roboz
Michael R. Savona
Michael R. McKeown
Kristin Stephens
David A. Roth
Jorge E. Cortes

TPS7071Background: SY-1425 (tamibarotene) is an orally available, synthetic retinoid approved in Japan for the treatment of relapsed/refractory (R/R) APL. SY-1425 is a more potent and selective ret...

Keywords:

Agonist
Retinoic acid receptor alpha
Cancer research
Myeloid leukemia
Pathology
Biomarker (medicine)
Medicine
Tamibarotene
Refractory
synthetic retinoid
adult patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations